ARS Pharma rises after Q2 revenue beats estimates

Shares of drug developer ARS Pharmaceuticals SPRY.O rise 3.7% to $17.28 premarket

Company reports Q2 revenue of $15.72 million, beating estimates of $13.78 million

Company expects regulatory approval for its nasal spray, neffy, in Canada, Japan and Australia by end of 2025, with commercial rollouts planned in H1 2026

"As the volume of neffy continues to increase, we anticipate that the economic factors for the remaining PBMs will continue to reduce prior authorization requirements," says Chief Commercial Officer Eric Karas

Expects regulatory approval for neffy in China in H1 2026

ARS Pharma had cash, cash equivalents, and short-term investments of $240.1 million as of June 30

Up to last close, stock up 57.9% YTD